Mirum Pharmaceuticals Completes Phase 3 Enrollment for Livmarli in Rare Liver Diseases; Topline Data Expected Q4 2026
MIRM has more than doubled off its 52-week low of $36.88.
Summary
Mirum Pharmaceuticals has announced the completion of enrollment for its Phase 3 EXPAND study of Livmarli (maralixibat) in additional rare cholestatic liver diseases. This milestone signifies a crucial step forward in the clinical development of the drug, expanding its potential market. The company anticipates releasing topline data from this study in the fourth quarter of 2026, providing a clear future catalyst for the stock. This progress is important for Mirum, a growing biotech firm, as it continues to leverage its existing product portfolio to address unmet medical needs and drive pipeline expansion. Investors will now focus on the upcoming data readout for further insights into Livmarli's expanded efficacy.
At the time of this announcement, MIRM was trading at $90.63 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $5.5B. The 52-week trading range was $36.88 to $109.28. This news item was assessed with positive market sentiment and an importance score of 7 out of 10. Source: Reuters.